Is It Time for Myriad to Concede in AMP v. Myriad for the Good of the Biotechnology Industry?

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

Will I lose my dignity?
Will someone care?
Will I wake tomorrow
From this nightmare?

"Will I," Rent

MyriadThe Supreme Court's grant of certiorari over the question "Are human genes patentable" had raised for many the specter of an uninformed generalist court rendering a decision containing dicta that would negatively affect biotechnology.  This possibility is real, in view of the voices raised against patenting human genes based on moral, policy, or ideological grounds.  While strongly felt, these sentiments are based, in large part, on a misunderstanding or mischaracterization of either the facts or the law, specifically patent law.  These misstatements include arguments based on patent claims somehow exerting an ownership interest in individual's DNA, or that isolated human nucleic acid claims preempt future research (in the face of thousands of published scientific journal articles published since the BRCA gene patents were granted), or that isolated DNA patents inhibit future technologies like personalized medicine.

This is an argument that might have been relevant 30 years ago, but at least two facts mitigate against resolving this issue now.  The first is that the day of the DNA patent claim is rapidly coming to a close.  These types of patents were first filed directed to specific genes encoding biologically relevant proteins having therapeutic benefits.  These include erythropoietin, tissue plasminogen activator, interferon, blood clotting Factors VIII and IX, and others.  (Indeed, one of the most compelling types of evidence not considered by any court in the Myriad case is the testimony of the tens or hundreds of thousands of patients whose lives have been saved or bettered by biotechnology drugs protected, in part, by so-called "gene patents.")  Myriad's BRCA gene patent claims are in this form, one of the reasons why these claims are not infringed by genetic diagnostic methods used today.

The vast majority of gene patent applications, however, were filled as the result of the Human Genome Project.  These patents are limited in at least three ways.  First, the U.S. Patent and Trademark Office has established a policy that patents will be granted only if an applicant provided on the filing date specific, substantial, and credible utility for the protein encoded by the claimed DNA.  This provision prevents an applicant from obtaining patent exclusivity unless the applicant shows that she establishes utility, a requirement of the patent statute, of the encoded protein.  (This requirement is related to the policy enunciated in Brenner v. Manson, where claims to methods for making steroid molecules were invalidated based on failure to disclose a utility for the steroid molecules made using the methods.)  Second, certain researchers (notably, Sir John Shulston in England) made certain that the sequence results of the HGP were published in public databases as soon as possible; doing so placed the sequences in the prior art and precluded patentability for any application filed after the sequences were made public.  Finally, because almost all of these patents were filed at the turn of the century, and the term of these patents will expire no later than 20 years after application filing, the "problem" of gene patents will disappear no later than 2020 (and in many instances much earlier even if a patent can be obtained under the enhanced utility requirements).

Another reason why the ACLU's challenge is anachronistic (except for those meaning to make an ideological point) is that present and future technology, such as genetic diagnostic testing or personalized medicine, is not prevented or inhibited by claims to isolated DNA molecules encoding a specific human protein.  This is a consequence of the history of these type of claims for providing means for producing biologically relevant proteins like EPO and TPA.  The claims require that the DNA is isolated and that it encodes the full-length protein, as defined by specific amino acid sequence.  (For these reasons these claims are exceedingly narrow, and do not broadly preempt:  for example, such claims are not literally infringed if the encoded protein differs by a single amino acid, meaning that a difference of a single methylene group (the difference between a valine and an isoleucine residue) is enough to take a species outside the scope of the claim.)  Modern gene sequencing methods used for diagnostics neither isolate DNA nor produce a full-length DNA molecule encoding the protein.  Rather, sequencing is performed in such a way that fragments of the DNA are produced in a reaction mixture and sequenced without isolation; what is produced is the sequence, a characteristic of the DNA molecule that is not protected by the patent.  (This is why infringement of isolated DNA claims does not lie by using the sequence information to, inter alia, interrogate a DNA database.)  And the Myriad case has established that method claims directed to merely comparing an individual's gene sequence with a reference sequence and disclosing mutations identified as indicating a risk of disease, without more, are not patent eligible (under either Bilski v Kappos or Mayo v. Prometheus).

So there appears to be no sound policy reason for having the Supreme Court render a decision on the patent eligibility of human genes.  Sadly, there is seemingly no sound business reason for Myriad Genetics to have the Court decide this question either.  Myriad's counsel, Greg Castanias, argued in the first Federal Circuit oral argument that the plaintiffs did not have standing because there was no redressability to their claim.  Specifically, Mr. Castanias argued that even if the Court ruled in plaintiffs' favor, Myriad had other patent claims that would prevent Dr. Harry Ostrer and other plaintiffs from providing BRCA gene diagnostic tests.  In addition, while these patents were undoubtedly important when Myriad was establishing its diagnostics business they are less important now.  Fifteen years and thousands of genetic tests (apparently without any failures) later, the company's reputation, experience and extensive database is far more valuable than the claims at issue.

Under these circumstances, the question must be asked whether the prudent thing for Myriad to do is grant Dr. Ostrer a covenant not to sue on all the patents and claims involved in this litigation.  The result would be to render the issues before the Court moot; regardless of the perceived importance of the Question Presented, even the Supreme Court is limited by Article III of the Constitution and cannot render an advisory opinion on this issue.  Such an action by Myriad would not only prevent this case from being decided, it would preclude the Court from including in its opinion dicta on the patent eligibility of isolated DNA from other species (which may have importance in fields like agriculture or biofuels) or other "products of nature" that may provide the basis for biologic and other types of drugs.  In view of the seemingly complete lack of any practical reason for having the Supreme Court decide this issue, and the risks to the progress provided for a generation by the biotechnology industry, nothing other than a desire to be vindicated remains to support seeing this case through to its conclusion.  Frankly, in view of what it at stake, such vindication is simply not enough.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!